Liquidity is rapidly depleting, with the company burning through cash and maintaining an OCF/NI ratio below 0.50, indicating a chronic inability to convert earnings into operational capital.
| Cash from Operations | -3.06M | -3.33M | -4.39M | -8.35M | -3.81M | -1.18M |
| Operating CF Margin % | - | -174.05% | -8722.42% | - | - | - |
| Operating CF Growth % | 120.2% | 24.14% | 47.43% | -119.06% | -223.83% | - |
| Net Income | -6.83M | -6.91M | -11.8M | -15.45M | -9.05M | -6.48M |
| Depreciation & Amortization | 178.67K | 215.05K | 197.26K | 124.79K | 242.56K | 242.12K |
| Stock-Based Compensation | 723.89K | 692.79K | 827.04K | 667.68K | 636.37K | 246.8K |
| Deferred Taxes | 0 | 0 | 0 | 0 | -194.59K | 2.52M |
| Other Non-Cash Items | 201.94K | -88.62K | 5.72M | 9.73M | 2.22M | 1.35M |
| Working Capital Changes | 2.85M | 2.76M | 669.49K | -3.42M | 2.34M | 952.69K |
| Change in Receivables | 347.93K | 345.99K | -101.38K | -204.56K | 0 | 0 |
| Change in Inventory | 387.02K | 370.85K | -108.7K | 204.56K | 0 | 0 |
| Change in Payables | 361.17K | 126.86K | -359.14K | -449.87K | 1.06M | 80.32K |
| Cash from Investing | -14.22K | -164.22K | -748.8K | -30.47K | -7.16K | -7.27K |
| Capital Expenditures | -14.22K | -14.22K | 0 | -30.47K | -7.16K | -7.27K |
| CapEx % of Revenue | 0.79% | 0.74% | - | - | - | - |
| Acquisitions | 0 | -150K | -748.8K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 154.44M |
| Cash from Financing | 2.62M | 4.04M | 2.38M | 11.16M | 3.93M | 1.2M |
| Debt Issued (Net) | -417K | -440.7K | -218.49K | -3.2M | 2.75M | 1.12M |
| Equity Issued (Net) | 3.04M | 4.48M | 2.69M | 41.07K | 1.06M | 3.19K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -2.29K | 0 |
| Other Financing | 0 | 0 | -86.31K | 14.32M | 125.88K | 67.82K |
| Net Change in Cash | -456.65K | 549.6K | -2.76M | 2.78M | 115.79K | 11.21K |
| Free Cash Flow | -3.08M | -3.34M | -4.39M | -8.38M | -3.44M | -1.18M |
| FCF Margin % | -171.43% | -174.79% | -8722.42% | - | - | - |
| FCF Growth % | 24.35% | 23.82% | 47.62% | -143.86% | -190.17% | - |
| FCF per Share | -1.62 | -1.94 | -0.21 | -0.40 | -0.17 | -0.06 |
| FCF Conversion (FCF/Net Income) | 0.45x | 0.48x | 0.42x | 0.54x | 0.42x | 0.18x |
| Interest Paid | 8.16K | 18.21K | 29.47K | 283.53K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 750K | 0 | 0 |
Liquidity and capital exhaustion
According to the provided financial data, XAGE exhibits a chronic inability to convert net income into operating cash flow, with the OCF/NI ratio frequently falling below 0.50, suggesting that reported losses significantly understate the actual cash drain required to sustain the company's current operational footprint.
The consistent gap between net income and operating cash flow indicates that non-cash items and working capital fluctuations are masking the severity of the underlying cash burn. Investors should interpret this divergence as a sign that the company's accounting earnings are not reflective of the actual capital intensity required to maintain its R&D and commercialization efforts.
As reported in quarterly financial statements, XAGE's free cash flow remains deeply negative, with the company burning through hundreds of thousands of dollars per quarter, a trend that underscores the lack of self-sustaining commercial momentum despite the recent surge in top-line revenue growth figures.
The persistent negative FCF margins, which have reached as low as -166% in recent periods, suggest that the company is far from achieving operational self-sufficiency. This trajectory implies that the business model is currently dependent on external financing to bridge the gap between its high operating costs and its limited revenue generation.
Based on the reported figures, XAGE's working capital changes are highly erratic, with swings ranging from a $1.6 million inflow to a $927.8 thousand outflow, indicating that the company's cash position is heavily influenced by lumpy, unpredictable timing of receivables and payables rather than stable operations.
This volatility in working capital suggests that the company may be struggling to manage its cash conversion cycle effectively as it attempts to scale. Such fluctuations often indicate that the company is either aggressively managing payables to preserve cash or experiencing significant delays in collecting payments from its distribution partners.
Financial statements reveal that stock-based compensation consistently adds back significant amounts to cash flow, often exceeding $100,000 per quarter, which obscures the true economic cost of talent acquisition and retention in a cash-constrained environment where liquidity is already at a critical, near-depleted level.
By relying on stock-based compensation to manage its expense profile, the company is effectively diluting shareholders to fund operations that are not yet cash-flow positive. Analysts should monitor these adjustments closely, as they represent a real economic cost that is being excluded from the headline operating cash flow figures.
Quick answers to the most common questions about buying XAGE stock.
Longevity Health Holdings Inc. (XAGE) generated $-3.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Longevity Health Holdings Inc. (XAGE) reported negative free cash flow of $3.3M in 2025, indicating capital requirements exceeded cash from operations.
Longevity Health Holdings Inc. (XAGE) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.